Detalles de la búsqueda
1.
Bimekizumab in patients with psoriatic arthritis, naive to biologic treatment: a randomised, double-blind, placebo-controlled, phase 3 trial (BE OPTIMAL).
Lancet
; 401(10370): 25-37, 2023 01 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-36493791
2.
Bimekizumab in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor-α inhibitors: a randomised, double-blind, placebo-controlled, phase 3 trial (BE COMPLETE).
Lancet
; 401(10370): 38-48, 2023 01 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-36495881
3.
IL-23 induces CLEC5A+ IL-17A+ neutrophils and elicit skin inflammation associated with psoriatic arthritis.
J Autoimmun
; 143: 103167, 2024 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-38301504
4.
Association of the clinical components in the distal interphalangeal joint synovio-entheseal complex and subsequent response to ixekizumab or adalimumab in psoriatic arthritis.
Rheumatology (Oxford)
; 2024 Feb 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-38341669
5.
Vaccination recommendations for adults receiving biologics and oral therapies for psoriasis and psoriatic arthritis: Delphi consensus from the medical board of the National Psoriasis Foundation.
J Am Acad Dermatol
; 90(6): 1170-1181, 2024 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-38331098
6.
Bimekizumab treatment in biologic DMARD-naïve patients with active psoriatic arthritis: 52-week efficacy and safety results from the phase III, randomised, placebo-controlled, active reference BE OPTIMAL study.
Ann Rheum Dis
; 82(11): 1404-1414, 2023 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-37696588
7.
Comparative effectiveness of guselkumab in psoriatic arthritis: updates to a systematic literature review and network meta-analysis.
Rheumatology (Oxford)
; 62(4): 1417-1425, 2023 04 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-36102818
8.
Guselkumab provides sustained domain-specific and comprehensive efficacy using composite indices in patients with active psoriatic arthritis.
Rheumatology (Oxford)
; 62(2): 606-616, 2023 02 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-35766811
9.
Upadacitinib as monotherapy and in combination with non-biologic disease-modifying antirheumatic drugs for psoriatic arthritis.
Rheumatology (Oxford)
; 61(8): 3257-3268, 2022 08 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-34864911
10.
Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNFα inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial.
Lancet
; 395(10230): 1115-1125, 2020 04 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-32178765
11.
Bimekizumab in patients with active psoriatic arthritis: results from a 48-week, randomised, double-blind, placebo-controlled, dose-ranging phase 2b trial.
Lancet
; 395(10222): 427-440, 2020 02 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-32035552
12.
Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): a double-blind, parallel-group, randomised, active-controlled, phase 3b trial.
Lancet
; 395(10235): 1496-1505, 2020 05 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-32386593
13.
Crossing the boundaries: IL-23 and its role in linking inflammation of the skin, gut and joints.
Rheumatology (Oxford)
; 60(Suppl 4): iv16-iv27, 2021 10 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-33961030
14.
Comparative effectiveness of guselkumab in psoriatic arthritis: results from systematic literature review and network meta-analysis.
Rheumatology (Oxford)
; 60(5): 2109-2121, 2021 05 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-33844022
15.
Resolution of enthesitis by guselkumab and relationships to disease burden: 1-year results of two phase 3 psoriatic arthritis studies.
Rheumatology (Oxford)
; 60(11): 5337-5350, 2021 11 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-33822898
16.
National Psoriasis Foundation COVID-19 Task Force guidance for management of psoriatic disease during the pandemic: Version 2-Advances in psoriatic disease management, COVID-19 vaccines, and COVID-19 treatments.
J Am Acad Dermatol
; 84(5): 1254-1268, 2021 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-33422626
17.
TNF-Induced Interstitial Lung Disease in a Murine Arthritis Model: Accumulation of Activated Monocytes, Conventional Dendritic Cells, and CD21+/CD23- B Cell Follicles Is Prevented with Anti-TNF Therapy.
J Immunol
; 203(11): 2837-2849, 2019 12 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-31659014
18.
Overview of the Grant Writing Workshop From the GRAPPA 2020 Annual Meeting.
J Rheumatol Suppl
; 97: 17-18, 2021 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-34074660
19.
GRAPPA Trainee Symposium 2020: A Summary of Oral and Poster Presentations.
J Rheumatol Suppl
; 97: 19-23, 2021 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-34074661
20.
Proceedings of the 2020 GRAPPA Collaborative Research Network (CRN) Meeting.
J Rheumatol Suppl
; 97: 4-9, 2021 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-34074658